JP2017538769A5 - - Google Patents

Download PDF

Info

Publication number: JP2017538769A5
Authority: JP; Japan
Prior art keywords: compound; salt; pharmaceutically acceptable; solvate; alkyl
Prior art date: 2015-12-11
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Withdrawn

Application number

JP2017533416A

Other languages

English (en)

Japanese (ja)

Other versions

JP2017538769A (ja

Filing date

2015-12-11

Publication date

2019-01-24

2015-12-11 Application filed filed Critical

2015-12-11 Priority claimed from PCT/IB2015/059548 external-priority patent/WO2016103097A1/en

2017-12-28 Publication of JP2017538769A publication Critical patent/JP2017538769A/ja

2019-01-24 Publication of JP2017538769A5 publication Critical patent/JP2017538769A5/ja

Status Withdrawn legal-status Critical Current

Links

150000003839 salts Chemical class 0.000 claims 28
150000001875 compounds Chemical class 0.000 claims 22
239000012453 solvate Substances 0.000 claims 12
125000000217 alkyl group Chemical group 0.000 claims 11
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 6
229910052736 halogen Inorganic materials 0.000 claims 6
150000002367 halogens Chemical class 0.000 claims 6
125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 5
229910052757 nitrogen Inorganic materials 0.000 claims 5
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 4
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 3
QEUAUMWHNLVMDZ-HXUWFJFHSA-N 6-(5-fluoroquinolin-7-yl)-3-[(3R)-3-methyl-2-oxopiperidin-3-yl]-1H-pyridin-2-one Chemical compound FC1=C2C=CC=NC2=CC(=C1)C1=CC=C(C(N1)=O)[C@@]1(C(NCCC1)=O)C QEUAUMWHNLVMDZ-HXUWFJFHSA-N 0.000 claims 2
BYEAHWXPCBROCE-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-ol Chemical compound FC(F)(F)C(O)C(F)(F)F BYEAHWXPCBROCE-UHFFFAOYSA-N 0.000 claims 1
OJVNYQOKTZLPPX-OAQYLSRUSA-N 3-[(3R)-3-methyl-2-oxopiperidin-3-yl]-6-(5-methylquinolin-3-yl)-1H-pyridin-2-one Chemical compound C[C@]1(C(NCCC1)=O)C=1C(NC(=CC=1)C=1C=NC2=CC=CC(=C2C=1)C)=O OJVNYQOKTZLPPX-OAQYLSRUSA-N 0.000 claims 1
URFCQPHIMBZYON-OAQYLSRUSA-N 3-[(3R)-3-methyl-2-oxopiperidin-3-yl]-6-(5-methylquinolin-7-yl)-1H-pyridin-2-one Chemical compound C[C@]1(C(NCCC1)=O)C=1C(NC(=CC=1)C1=CC(=C2C=CC=NC2=C1)C)=O URFCQPHIMBZYON-OAQYLSRUSA-N 0.000 claims 1
NYMPHOZUBJYHBQ-HXUWFJFHSA-N 3-[(3R)-3-methyl-2-oxopyrrolidin-3-yl]-6-(5-methylquinolin-3-yl)-1H-pyridin-2-one Chemical compound C[C@]1(C(NCC1)=O)C=1C(NC(=CC=1)C=1C=NC2=CC=CC(=C2C=1)C)=O NYMPHOZUBJYHBQ-HXUWFJFHSA-N 0.000 claims 1
QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 claims 1
ALGSMAYBBGCDSR-HXUWFJFHSA-N 6-(5-chloroquinolin-7-yl)-3-[(3R)-3-methyl-2-oxopiperidin-3-yl]-1H-pyridin-2-one Chemical compound ClC1=C2C=CC=NC2=CC(=C1)C1=CC=C(C(N1)=O)[C@@]1(C(NCCC1)=O)C ALGSMAYBBGCDSR-HXUWFJFHSA-N 0.000 claims 1
JXKXDDNPECXKSM-HSZRJFAPSA-N 6-(5-cyclopropylquinolin-7-yl)-3-[(3R)-3-methyl-2-oxopiperidin-3-yl]-1H-pyridin-2-one Chemical compound C1(CC1)C1=C2C=CC=NC2=CC(=C1)C1=CC=C(C(N1)=O)[C@@]1(C(NCCC1)=O)C JXKXDDNPECXKSM-HSZRJFAPSA-N 0.000 claims 1
KPRFPENKXRBQRF-JOCHJYFZSA-N 6-(5-ethylquinolin-7-yl)-3-[(3R)-3-methyl-2-oxopiperidin-3-yl]-1H-pyridin-2-one Chemical compound C(C)C1=C2C=CC=NC2=CC(=C1)C1=CC=C(C(N1)=O)[C@@]1(C(NCCC1)=O)C KPRFPENKXRBQRF-JOCHJYFZSA-N 0.000 claims 1
ICRVRXNPWUOCMP-IVAFLUGOSA-N CCc1cc(cc2ncccc12)C1=NC(=O)C(C=C1)[C@@]1(C)CCCNC1=O Chemical compound CCc1cc(cc2ncccc12)C1=NC(=O)C(C=C1)[C@@]1(C)CCCNC1=O ICRVRXNPWUOCMP-IVAFLUGOSA-N 0.000 claims 1
ZTBLZTHRYZXYNZ-WBPHRXDCSA-N C[C@@]1(CCCNC1=O)C1C=CC(=NC1=O)c1cc(C2CC2)c2cccnc2c1 Chemical compound C[C@@]1(CCCNC1=O)C1C=CC(=NC1=O)c1cc(C2CC2)c2cccnc2c1 ZTBLZTHRYZXYNZ-WBPHRXDCSA-N 0.000 claims 1
SGMZEERLWJABMZ-YBMSBYLISA-N C[C@@]1(CCCNC1=O)C1C=CC(=NC1=O)c1cc(Cl)c2cccnc2c1 Chemical compound C[C@@]1(CCCNC1=O)C1C=CC(=NC1=O)c1cc(Cl)c2cccnc2c1 SGMZEERLWJABMZ-YBMSBYLISA-N 0.000 claims 1
SSQLJNRCSCKPFA-MYKUNDNFSA-N Cc1cc(cc2ncccc12)C1CCC(C(=O)N1)[C@@]1(C)CCCNC1=O Chemical compound Cc1cc(cc2ncccc12)C1CCC(C(=O)N1)[C@@]1(C)CCCNC1=O SSQLJNRCSCKPFA-MYKUNDNFSA-N 0.000 claims 1
ZUCVEFCHDRKBHT-MYKUNDNFSA-N Cc1cccc2ncc(cc12)C1CCC(C(=O)N1)[C@@]1(C)CCCNC1=O Chemical compound Cc1cccc2ncc(cc12)C1CCC(C(=O)N1)[C@@]1(C)CCCNC1=O ZUCVEFCHDRKBHT-MYKUNDNFSA-N 0.000 claims 1
RXTUYFXTGPOYIV-ALLBUHFWSA-N Cc1cccc2ncc(cc12)C1CCC(C(=O)N1)[C@@]1(C)CCNC1=O Chemical compound Cc1cccc2ncc(cc12)C1CCC(C(=O)N1)[C@@]1(C)CCNC1=O RXTUYFXTGPOYIV-ALLBUHFWSA-N 0.000 claims 1
239000000654 additive Substances 0.000 claims 1
230000000996 additive effect Effects 0.000 claims 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
150000004682 monohydrates Chemical class 0.000 claims 1
239000008194 pharmaceutical composition Substances 0.000 claims 1
238000007614 solvation Methods 0.000 claims 1

JP2017533416A 2014-12-22 2015-12-11 プロスタグランジンｅｐ３受容体の拮抗薬 Withdrawn JP2017538769A (ja)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US201462095337P	2014-12-22	2014-12-22
US62/095,337		2014-12-22
US201562259528P	2015-11-24	2015-11-24
US62/259,528		2015-11-24
PCT/IB2015/059548 WO2016103097A1 (en)	2014-12-22	2015-12-11	Antagonists of prostaglandin ep3 receptor

Publications (2)

Publication Number	Publication Date
JP2017538769A JP2017538769A (ja)	2017-12-28
JP2017538769A5 true JP2017538769A5 (2)	2019-01-24

Family

ID=55077554

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP2017533416A Withdrawn JP2017538769A (ja)	2014-12-22	2015-12-11	プロスタグランジンｅｐ３受容体の拮抗薬

Country Status (7)

Country	Link
US (1)	US9738626B2 (2)
EP (1)	EP3237401B1 (2)
JP (1)	JP2017538769A (2)
CA (1)	CA2915470A1 (2)
TW (1)	TW201632513A (2)
UY (1)	UY36455A (2)
WO (1)	WO2016103097A1 (2)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US10590083B2 (en)	2017-08-10	2020-03-17	Janssen Pharmaceutica Nv	Pyridin-2-one derivatives of formula (I) useful as EP3 receptor antagonists
US10399944B2 (en)	2017-08-10	2019-09-03	Janssen Pharmaceutica Nv	Pyridin-2-one derivatives of formula (III) useful as EP3 receptor antagonists
US10336701B2 (en)	2017-08-10	2019-07-02	Janssen Pharmaceutica Nv	Pyridin-2-one derivatives of formula (II) useful as EP3 receptor antagonists
EP3793559A1 (en)	2018-05-17	2021-03-24	Bayer Aktiengesellschaft	Substituted dihydropyrazolo pyrazine carboxamide derivatives
WO2021094210A1 (en)	2019-11-12	2021-05-20	Bayer Aktiengesellschaft	Substituted pyrazine carboxamide derivatives as prostaglandin ep3 receptor antagonists
WO2021094208A1 (en)	2019-11-12	2021-05-20	Bayer Aktiengesellschaft	Substituted imidazo pyrimidine ep3 antagonists
WO2021094209A1 (en)	2019-11-12	2021-05-20	Bayer Aktiengesellschaft	Substituted pyrrolo triazine carboxamide derivatives as prostaglandin ep3 receptor antagonists
EP4319734A2 (en)	2021-04-07	2024-02-14	Hadasit Medical Research Services&Development Ltd.	Prostaglandin receptor 3 (ep3) antagonists for use in the treatment of diabetes
CN116106398A (zh) *	2022-08-03	2023-05-12	南方医科大学珠江医院	用于诊断ckd的标志物
JPWO2024190777A1 (2) *	2023-03-13	2024-09-19

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4219483A (en)	1978-09-11	1980-08-26	Pfizer Inc.	4-Pyrone prostaglandin antagonists
US5612359A (en)	1994-08-26	1997-03-18	Bristol-Myers Squibb Company	Substituted biphenyl isoxazole sulfonamides
TW536540B (en)	1997-01-30	2003-06-11	Bristol Myers Squibb Co	Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
HUP0104634A3 (en)	1998-07-06	2002-11-28	Bristol Myers Squibb Co	Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
MY125533A (en)	1999-12-06	2006-08-30	Bristol Myers Squibb Co	Heterocyclic dihydropyrimidine compounds
CA2439152C (en)	2001-02-28	2008-06-17	Merck & Co., Inc.	Acylated piperidine derivatives as melanocortin-4 receptor agonists
US20030195205A1 (en)	2001-11-02	2003-10-16	Pfizer Inc.	PDE9 inhibitors for treating cardiovascular disorders
CN1642599A (zh)	2002-02-27	2005-07-20	辉瑞产品公司	Acc抑制剂
DE10238724A1 (de)	2002-08-23	2004-03-04	Bayer Ag	Alkyl-substituierte Pyrazolpyrimidine
DE10238723A1 (de)	2002-08-23	2004-03-11	Bayer Ag	Phenyl-substituierte Pyrazolyprimidine
US20040220186A1 (en)	2003-04-30	2004-11-04	Pfizer Inc.	PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease
PL1753748T3 (pl)	2004-05-12	2010-01-29	Pfizer Prod Inc	Pochodne proliny i ich zastosowanie jako inhibitorów peptydazy dipeptylowej IV
AP2006003768A0 (en)	2004-05-25	2006-10-31	Pfizer Prod Inc	TetraazabenzoÄeÜazulene derivatives and analogs tehereof
KR101213912B1 (ko)	2004-08-26	2012-12-18	액테리온 파마슈티칼 리미티드	Ｃｒｔｈ2 길항제로서의2-설파닐-벤조이미다졸-1-일-아세틱 애시드 유도체
PA8660701A1 (es)	2005-02-04	2006-09-22	Pfizer Prod Inc	Agonistas de pyy y sus usos
WO2007027630A2 (en)	2005-08-30	2007-03-08	Smithkline Beecham Corporation	Genes associated with type ii diabetes mellitus
EP2010520B1 (en)	2006-04-20	2012-09-12	Pfizer Products Inc.	Heterobicyclic amides for the prevention and treatment of glucokinase-mediated diseases
BRPI0721053A2 (pt)	2006-11-29	2014-07-29	Pfizer Prod Inc	INIBIDORES DE ESPIROCETONA ACETIL-CoA CARBOXILASE
BRPI0811444A2 (pt)	2007-05-10	2014-10-29	Pfizer Ltd	Derivados de azetidina e seu uso como antagonistas da prostaglandina e2.
RS52166B (sr)	2007-05-11	2012-08-31	Pfizer Inc.	Amino-heterociklična jedinjenja
US20090036425A1 (en)	2007-08-02	2009-02-05	Pfizer Inc	Substituted bicyclolactam compounds
WO2009144555A1 (en)	2008-05-28	2009-12-03	Pfizer Inc.	Pyrazolospiroketone acetyl-coa carboxylase inhibitors
JP5435592B2 (ja)	2008-05-28	2014-03-05	ファイザー・インク	ピラゾロスピロケトンアセチルＣｏＡカルボキシラーゼ阻害剤
JP2011529483A (ja)	2008-07-29	2011-12-08	ファイザー・インク	フッ素化ヘテロアリール
AU2009286380B2 (en)	2008-08-28	2011-09-15	Pfizer Inc.	Dioxa-bicyclo[3.2.1.]octane-2,3,4-triol derivatives
TW201038580A (en)	2009-02-02	2010-11-01	Pfizer	4-amino-5-oxo-7,8-dihydropyrimido[5,4-f][1,4]oxazepin-6(5H)-yl)phenyl derivatives
EP2604604A1 (en)	2009-03-11	2013-06-19	Pfizer Inc	Benzofuranyl derivatives used as glucokinase inhibitors
CA2754685A1 (en)	2009-03-11	2010-09-16	Pfizer Inc.	Substituted indazole amides
WO2010106457A2 (en)	2009-03-20	2010-09-23	Pfizer Inc.	3-oxa-7-azabicyclo[3.3.1]nonanes
US20120052130A1 (en)	2009-05-08	2012-03-01	Pfizer Inc.	Gpr 119 modulators
CA2759843A1 (en)	2009-05-08	2010-11-10	Pfizer Inc.	Gpr 119 modulators
NZ596467A (en)	2009-06-05	2014-01-31	Pfizer	L- ( piperidin-4-yl) -pyrazole derivatives as gpr 119 modulators
WO2011005611A1 (en)	2009-07-09	2011-01-13	Merck Sharp & Dohme Corp.	Neuromedin u receptor agonists and uses thereof
KR101548443B1 (ko)	2011-02-23	2015-08-28	화이자 인코포레이티드	신경 장애의 치료를 위한 이미다조[5,1-f][1,2,4]트라이아진
CA2836851C (en)	2011-06-07	2016-06-21	Christopher J. Helal	Pyrazolo[3,4-d]pyrimidine compounds and their use as pde2 inhibitors and/or cyp3a4 inhibitors
CA2926568C (en)	2013-10-09	2017-09-05	Pfizer Inc.	Antagonists of prostaglandin ep3 receptor

2015
- 2015-12-11 EP EP15821169.8A patent/EP3237401B1/en not_active Not-in-force
- 2015-12-11 WO PCT/IB2015/059548 patent/WO2016103097A1/en not_active Ceased
- 2015-12-11 JP JP2017533416A patent/JP2017538769A/ja not_active Withdrawn
- 2015-12-16 US US14/970,930 patent/US9738626B2/en not_active Expired - Fee Related
- 2015-12-17 CA CA2915470A patent/CA2915470A1/en not_active Abandoned
- 2015-12-17 TW TW104142513A patent/TW201632513A/zh unknown
- 2015-12-18 UY UY0001036455A patent/UY36455A/es not_active Application Discontinuation

Publication	Publication Date	Title
JP2017538769A5 (2)	2019-01-24
HRP20200538T1 (hr)	2020-07-10	Derivati pirimidina za liječenje virusnih infekcija
JP2017504635A5 (2)	2018-03-08
JP2013523802A5 (2)	2014-05-15
JP2016521710A5 (2)	2017-01-26
JP2013542261A5 (2)	2014-12-25
JP2012140432A5 (2)	2013-04-11
JP2016513660A5 (2)	2017-03-30
JP2017509586A5 (2)	2018-01-11
MY187617A (en)	2021-10-04	Bridged ring compounds as hepatitis c virus (hcv) inhibitors and pharmaceutical applications thereof
JP2016530259A5 (2)	2017-09-21
JP2017517512A5 (2)	2018-08-02
JP2019501125A5 (2)	2019-12-26
JP2016501250A5 (2)	2017-01-19
JP2016507581A5 (2)	2017-03-02
JP2015535839A5 (2)	2016-11-10
JP2016518328A5 (2)	2017-04-13
JP2017526701A5 (2)	2019-09-12
JP2015512883A5 (2)	2016-04-28
JP2017537937A5 (2)	2018-12-13
JP2017506666A5 (2)	2018-02-22
HRP20192279T1 (hr)	2020-03-06	Novi spojevi imidazopiridazina i njihova uporaba
JP2016528273A5 (2)	2017-09-28
JP2015500842A5 (2)	2016-02-04
JP2013502441A5 (2)	2013-09-19